Role of early continuous regional arterial infusion of protease inhibitor and antibiotic in nonsurgical treatment of acute necrotizing pancreatitis

Digestion. 1999:60 Suppl 1:9-13. doi: 10.1159/000051446.

Abstract

This paper reviewed our experience with the nonsurgical management of acute necrotizing pancreatitis (ANP) by continuous regional arterial infusion (CRAI) of protease inhibitor (nafamostat mesilate, 240 mg/day) and antibiotic (imipenem, 0.5 g every 12 h). 47 patients with ANP admitted within 7 days were treated with intensive care and CRAI for 5 days prospectively. 40 patients responded to CRAI therapy and the mortality rate in these patients was 2.5%. 7 patients (14. 9%) did not respond to CRAI. 5 of 7 nonresponders died of multiple organ failure although pancreatic necrosis was persistently sterile. The remaining 2 patients who underwent necrosectomy for infected pancreatic necrosis recovered after surgery. In 34 patients treated with CRAI in the early stage within 72 h after the onset, 31 (91.2%) responded. The mortality rate was 5.9% and the incidence of infected pancreatic necrosis was 2.9% in these 34 patients. These results demonstrated that most patients with ANP responded to conservative management combined with CRAI with nafamostat and imipenem when employed within 72 h after the onset. Early intervention of CRAI with protease inhibitor and antibiotic has a significant role in the nonsurgical management of ANP.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Benzamidines
  • Drug Therapy, Combination
  • Female
  • Guanidines / administration & dosage*
  • Guanidines / therapeutic use
  • Humans
  • Imipenem / administration & dosage*
  • Imipenem / therapeutic use
  • Infusions, Intra-Arterial
  • Male
  • Middle Aged
  • Pancreatitis, Acute Necrotizing / drug therapy*
  • Pancreatitis, Acute Necrotizing / pathology
  • Protease Inhibitors / administration & dosage*
  • Protease Inhibitors / therapeutic use
  • Retrospective Studies
  • Thienamycins / administration & dosage*
  • Thienamycins / therapeutic use
  • Treatment Outcome

Substances

  • Benzamidines
  • Guanidines
  • Protease Inhibitors
  • Thienamycins
  • Imipenem
  • nafamostat